Fulgent Genetics (FLGT) Cost of Revenue (2015 - 2026)

Fulgent Genetics has disclosed Cost of Revenue across 12 years of filings, most recently posting $59.7 million for Q2 2026.

• In Q2 2026, Cost of Revenue rose 26.06% year-over-year to $59.7 million; the TTM figure through Jun 2026 stood at $208.7 million (up 14.77% YoY), while the FY2025 annual figure was $191.8 million, up 8.82% from the prior year.
• Cost of Revenue came in at $59.7 million for Q2 2026 at Fulgent Genetics, up from $49.6 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $77.7 million in Q1 2022 to a low of $42.4 million in Q1 2024.
• Average Cost of Revenue over 5 years is $50.8 million, with a median of $47.4 million recorded in 2023.
• Year-over-year, Cost of Revenue jumped 67.51% in 2022 and slumped 39.07% in 2023.
• Over 5 years, Cost of Revenue stood at $54.7 million in 2022, then dropped by 17.25% to $45.3 million in 2023, then dropped by 2.01% to $44.4 million in 2024, then advanced by 14.4% to $50.8 million in 2025, then rose by 17.65% to $59.7 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $59.7 million in Q2 2026, $49.6 million in Q1 2026, and $50.8 million in Q4 2025.